论文部分内容阅读
目的探讨罗格列酮(RGZ)对2型糖尿病(T2DM)患者血管内皮功能和高敏C反应蛋白(hsC-RP)的影响。方法选择40例T2DM患者(DM组)给予口服RGZ 12周。观察治疗前后FPG、FIns、HbA_1c、hsC-RP、血管性假血友病因子(vWF)和血栓调节蛋白(TM)水平。另没30名健康正常人为对照(NC)组。结果 DM组给药前与NC组比较,血浆vWF、TM和hsC-RP均明显升高;经RGZ治疗12周后,患者FPG、FIns、HbA_1c和胰岛素敏感指数均明显改善,且血浆vWF、TM和hsC-RP均明显下降。结论 RGZ在降低血糖和提高胰岛素敏感性同时,能改善患者血管内皮功能,降低炎症反应。
Objective To investigate the effect of rosiglitazone (RGZ) on vascular endothelial function and high-sensitivity C-reactive protein (hsC-RP) in type 2 diabetes mellitus (T2DM). Methods Forty T2DM patients (DM group) were given oral RGZ for 12 weeks. The levels of FPG, FIns, HbA_1c, hsC-RP, vWF and TM were observed before and after treatment. The other 30 healthy controls were control group (NC). Results The levels of vWF, TM and hsC-RP in plasma were significantly increased in DM group compared with those in NC group. The levels of FPG, FIns, HbA 1c and insulin sensitivity were significantly improved after treatment with RGZ for 12 weeks, and plasma vWF, TM And hsC-RP were significantly decreased. Conclusions RGZ can improve vascular endothelial function and reduce inflammatory reaction in patients with lower blood glucose and insulin sensitivity.